In this episode, Brendan is joined by Tom Otis, a researcher and academic in the field of neurodegenerative diseases, discusses the latest advancements in understanding and treating conditions such as spinocerebellar ataxia (SCA) and amyotrophic lateral sclerosis (ALS). He explains the genetic basis of these diseases and the potential of CRISPR technology in developing targeted therapies. Tom emphasizes the importance of interdisciplinary collaboration and patient advocacy in driving progress in the field. He also highlights the role of physical activity in maintaining overall health and its potential impact on neurological diseases. Overall, Tom's work aims to improve the lives of individuals affected by these conditions and bring about transformative therapies.
To learn more about Tom's work and his current endeavors as the Chief Scientific Officer at Lario Therapeutics and as a Professor in Neuroscience at University College London, visit the links below:
Takeaways
Chapters
00:00- Introduction
01:16- Overview of Spinal Cerebellar Ataxia (SCA) and ALS
03:56- The Impact of CRISPR on Genomic Research
05:18- Motivation to Study Neurodegenerative Diseases
07:23- Challenges in Identifying Genetic Causes of Neurodegenerative Diseases
08:33- Advances in Genetics and Precision Medicine
10:17- Current Treatments and Therapies for ALS
13:55- Research on ALS and Genetic Subsets
14:31- The Link Between Repeated Head Trauma and Neurodegenerative Diseases
16:24- Collaboration with Researchers in Parkinson's and Alzheimer's
17:40- The Importance of Patient Advocacy and Awareness
20:43- Interdisciplinary Work in Neurodegenerative Diseases
23:42- Challenges in Disseminating Information and Selling Treatments
25:08- The Cost and Access to Pharmaceuticals
27:40- The Nature of Ataxias and Current Treatments
28:19- The Role of Public Advocacy and Awareness in Rare Diseases
30:18- The Work of a Neuroscientist and Opportunities in the Field
34:43- Understanding Ataxia and its Manifestation
